BioSig’s PURE EP System to be Featured in a Live Patient Case During Annual International Symposium on Ventricular Arrhythmias
October 12 2021 - 9:15AM
BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the
"Company"), a medical technology company commercializing an
innovative signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that its flagship technology would be
featured in a live patient case streamed during the 16th Annual
International Symposium on Ventricular Arrhythmias: Pathophysiology
& Therapy (“VT 2021”), held virtually on October 15-16, 2021.
VT 2021 has been developed to meet the educational needs of
electrophysiologists, cardiologists, and other physicians and
associated professionals interested in the pathophysiology and
management of ventricular arrhythmias. The event is hosted by the
Department of Medicine, Division of Cardiology, University of
Pennsylvania Health System in Philadelphia, PA, and the Division of
Cardiology, The Mount Sinai Hospital in New York, NY.
“Treatments for ventricular arrhythmias have historically been
complex due to the very challenging nature of these conditions. We
are focusing on uncovering important additional physiologic
information to hopefully improve the ventricular arrhythmia
treatments, and we are thrilled to be included in the live case
coverage during this year’s VT Symposium that is solely focused on
complex cardiac arrhythmias. We want to thank the course directors
and the global faculty for opening this important educational event
to all stakeholders and look forward to the two days of insightful
sessions,” commented Kenneth L. Londoner, Chairman, and CEO of
BioSig Technologies, Inc.
For more information about the event, please visit
www.vtsymposium.com.
To date, over 70 physicians have completed over 1500 patient
cases with the PURE EP™ System across thirteen clinical sites.
Clinical data acquired by the PURE EP™ System in a multi-center
study at Texas Cardiac Arrhythmia Institute at St. David’s Medical
Center, Mayo Clinic Jacksonville and Massachusetts General Hospital
was recently published in the Journal of Cardiovascular
Electrophysiology and is available electronically with open access
via the Wiley Online Library. Study results showed 93% consensus
across the blinded reviewers with a 75% overall improvement in
intracardiac signal quality and confidence in interpreting PURE EP™
signals over conventional sources.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company's first product, PURE EP™ System, is a computerized
system intended for acquiring, digitizing, amplifying, filtering,
measuring and calculating, displaying, recording, and storing of
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024